More recently, to elucidate the underlying mechanism of resistance to anti‐PD‐1 therapy, 10 patients with hepatocellular carcinoma (HCC) who were treated with anti‐PD‐1 therapy were divided into responsive and nonresponsive tumor patients, and the results revealed that GUSB amplification in nonresponding tumor patients was markedly greater than that in responding tumor patients. Here, GUSB is linked to hepatocellular carcinoma.